Vanguard Group Inc. acquired a new stake in Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,467,011 shares of the company's stock, valued at approximately $39,932,000. Vanguard Group Inc. owned 1.40% of Metsera as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also made changes to their positions in the company. New York State Common Retirement Fund purchased a new position in shares of Metsera in the first quarter valued at approximately $131,000. Bank of New York Mellon Corp acquired a new stake in Metsera in the first quarter valued at approximately $884,000. TD Asset Management Inc acquired a new stake in Metsera in the first quarter valued at approximately $2,091,000. Jennison Associates LLC acquired a new stake in Metsera in the first quarter valued at approximately $9,679,000. Finally, Massachusetts Financial Services Co. MA acquired a new stake in Metsera in the first quarter valued at approximately $13,111,000.
Metsera Stock Performance
Shares of Metsera stock traded up $0.25 during trading on Monday, reaching $35.29. The company's stock had a trading volume of 1,057,997 shares, compared to its average volume of 1,354,825. The company has a 50-day moving average price of $34.11 and a two-hundred day moving average price of $28.50. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $47.40.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) EPS for the quarter.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Bank of America raised their target price on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday. Wall Street Zen raised shares of Metsera from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Guggenheim raised their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Metsera has a consensus rating of "Buy" and a consensus price target of $59.00.
Check Out Our Latest Stock Report on MTSR
About Metsera
(
Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
